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INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by
the presence of atypical promyelocytes in bone marrow and
peripheral blood. APL is distinguished from other subtypes
of acute myeloid leukemia (AML) by its distinctive morphol-
ogy, younger patient age at presentation, specific chromoso-
mal abnormality, associated coagulopathy, and unique response
to treatment with retionic acid. All-trans retinoic acid (ATRA)
and intensive chemotherapy with ara-C and anthracycline is
recommended as the standard treatment for APL (1). Although
ATRA has improved the outcome of APL, early bleeding
diathesis and recurrence are main causes of death in patients
with APL. 
The involvement of central nervous system (CNS) in AML
is an uncommon finding. Patients at the highest risk for de-
veloping the leukemia in CNS include those with a high cir-
culating blast count, elevated lactate dehydrogenase activity,
and one of the monocytic leukemic subtypes (2, 3). Moreover,
leptomeningeal leukemic infiltration is rarely observed in patients
with APL.
We report a case of leptomeningeal relapse in a patient with
a variant APL who had achieved complete remission after
ATRA, idarubicin and cytarabine therapy. Furthermore, we
discuss the clinical manifestation and treatment of APL in
CNS in comparison of the results from our patients with those
of the previously reported cases.
CASE REPORT
A 41 yr-old man was presented with fever and generalized
petechiae. The full blood count showed a hemoglobin level
of 7.7 g/dL, a WBC count of 38.3×109/L consisting of 84%
blasts, and a platelet count of 25×109/L. A coagulation test
demonstrated severe disseminated intravascular coagulation
(DIC), with a prothrombin time of 15 sec, a partial thrombo-
plastin time of 81 sec, and a fibrinogen of 100 mg/dL. A bone
marrow examination showed APL, which was confirmed by
the presence of t(15;17)(q22;q21) on karyotypic analysis and
PML/RARA on molecular analysis. Flow cytometry revealed
leukemic cells positive for CD13 and CD33 expression, and
negative for the expression of HLA-DR. Induction chemother-
apy with idarubicin, ara-C (idarubicin 12 mg/m2/day intra-
venous i.v. on Days 1-3, ara-C100 mg/m2/day continuous iv
for 24 hr on Days 1-7) and ATRA at 45 mg/m2, which was
scheduled to be given until 30 days after complete remission,
led to complete remission on Day 25 of the treatment. Anal-
ysis of bone marrow revealed a normal karyotype as well as
absence of the PML/RARA rearrangement. The patient re-
ceived a consolidation with three consecutive courses of idaru-
bicin, and then a maintenance with ATRA (at 45 mg/m2 on
Days 1-15, every other month for 2 yr).
Ten months later, he complained of a mild non-specific
headache for two weeks of duration. The physical examination
was unremarkable. His complete blood counts were normal.
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Meningeal Relapse in a Patient with Acute Promyelocytic Leukemia
: A Case Report and Review of the Literature
The involvement of central nervous system is rare in acute promyelocytic leukemia
(APL). We report a APL patient of a 41 yr-old Korean male who presented with
fever and petechia. Complete molecular remission was achieved with all-trans
retinoic acid (ATRA), idarubicin, and cytarabine. Ten months later, he complained
of a mild headache. The results of the physical examination and the complete blood
counts were normal. The examination of cerebrospinal fluid showed the presence
of promyelocyte. Bone marrow studies showed cytogenetic remission but with
molecular relapse. He was treated with intrathecal and systemic chemotherapy. 
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Magnetic resonance imaging study showed multifocal lep-
tomeningeal enhancement in both the frontal and parietal
areas in enhanced T1-weighted image. Examination of cere-
brospinal fluid (CSF) showed the presence of atypical promye-
locytes (Fig. 1). The bone marrow smear showed a complete
hematologic and cytogenetic remission, but molecular stud-
ies showed the presence of PML/RARA rearrangement in the
bone marrow and in the CSF. 
The diagnosis of meningeal relapse of APL was made, and
he was treated with intrathecal methotrexate and ara-C (me-
thotrexate 12 mg and ara-C 100 mg administered twice a
week for four weeks), followed by high-dose systemic chemo-
therapy (ara-C 3.0 g/m2 i.v. b.i.d. on Days 1-4, mitoxantrone
12 mg/m2/day i.v. on Days 3-5). At the end of the intrathecal
chemotherapy his CSF analysis became normal, but blood
and bone marrow evaluations at this time showed hemato-
logic relapse. He died of neutropenic fever on Day 12 of his
systemic therapy.
DISCUSSION
Extramedullary leukemic infiltration is rarely observed in
patients with APL. The extramedullary sites reported are skin,
CNS, middle ear, lung, lymph node, mediastinum, thymus,
spine, breast, pelvis, and gingiva. The most common site is
skin (4). To our knowledge, only 31 cases of APL in CNS have
been reported (4-25). A summary of 21 cases of APL in CNS
is listed in Table 1. Fourteen of those 19 patients were male.
The age range of these patients was from 13 to 73 yr with a
median age of 39. Twenty patients showed evidence of APL in
CNS at the time of relapse. Only one case who had been treat-
ed for a non-Hodgkin’s lymphoma with chemotherapy and
Fig. 1. Cells in cerebrospinal fluid with APL morphologic feature
are noted (peroxidase stain, ×1,000).
No.
Age (yr)/
Sex
Initial WBC
( / L)
Pre-relapse
therapy
CR duration
(months)
Presentation at
CNS relapse
BM state
at relapse
Post relapse 
therapy
Follow up
Reference
No.
1 34/M 61 ATRA, CT 2 H, V NS ATRA, IT, CT, RT NS 5
2 39/M 35 ATRA, CT 8 H, N, V, diplopia NS IT, RT CR 5
3 63/M 67 AS2O3 11 Motor weakness Relapse  ATRA, IT CR for 3 mo 6
4 19/M NS ATRA, CT 5 H NS AS2O3, IT, RT CR for 17 mo 7
5 49/F 5.3 ATRA, CT 2 NS Relapse Refuse Died 1 mo later 8
6 37/M 98 ATRA, CT 2 Seizure Relapse IT, CT, RT Died 2 mo later 8
7 26/M 4.4 AS2O3 2nd CR 8 Vertigo  HR RT Died 2 days later 9
8 33/M 54.6 ATRA, CT 16 H, Convulsion MR IT Resistant to IT 10
9 40/M 33 ATRA, CT 1 H HR IT, alloSCT Died 5 mo later 11
10 13/F NS ATRA, CT 144 H, parotid mass MR ATRA Relapsed 22 mo later 12
11 40/M 14.6 ATRA, CT 2nd CR 10 NS NS NS Lived for 22 mo 13
12 32/M 35.1 ATRA, CT 2nd CR 3 NS NS NS Relapsed 5 mo later 13
13 30/M 6.2 ATRA, CT 9 H, double vision MR IT, CT Relapsed 10 mo later 14
14 50/M 7.5 ATRA, CT 5 H, V, visual disturbance HR IT, CT CR 15
15 46/F 307 CT 5 Seizure Relapse ATRA, RT NS 16
16 37/F NS CT 2nd CR 1 Visual acuity decreased Relapse ATRA Lived for 3 mo 17
17 43/F 1.5 H, N IT, CT, RT Lived for 13 mo 18
18 42/M 10 CT 8 H, V HR IT, RT Died 2 mo later 19
19 73/M 15.5 ATRA, CT 18 H, loss of sight NS surgery Died 20 days later 21
20 37/M 98.1 ATRA, CT 2 Seizure  Relapse  IT, CT, RT Died 2 mo later 22
21 69/M 9 ATRA, CT 6 H, ataxic gait Relapse  ATRA, IT, RT Died 6 mo later 25
Table 1. Reported cases of acute promyelocytic leukemia of the central nervous system
NS, not stated; CT, chemotherapy; CR, complete remission; H, headache; V, vomiting; N, nausea; Relapse hematologic relapse, HR, hematologic
remission; MR, molecular remission; IT, intrathecal chemotherapy; RT, radiotherapy.Meningeal Relapse in Acute Promyelocytic Leukemia 313
radiotherapy ten months ago had an intracerebral leukemic
mass at the onset of leukemia (18). Of the 20 relapsed patients,
the duration of remission ranged from 1 to 144 months, with
a median of five months. Four patients were in a secondary
remission state. Magnetic resonance imaging study or CT
scan was performed on ten patients; seven cases showed evi-
dence of mass and three cases did not show any pathologic
alteration. Magnetic resonance imaging study from our case
showed leptomeningeal enhancement only without mass for-
mation. Lumbar puncture was performed in all patients, and
the result showed that all patients had leukemic cells in the
CSF. 
The symptoms of APL in CNS are headache, vertigo, nausea,
vomiting, visual disturbance, motor weakness, and seizure.
In our case, he complained of a non-specific, mild headache.
Although CNS involvement of APL is rare, CSF studies should
be performed when symptoms of CNS occur. Interestingly,
recurrence in CNS did not coincide with a hematologic relapse.
Hematologic remission was maintained in nine cases when
a CNS relapse was found (5, 7, 9-12, 14, 15, 19). A molecu-
lar study to find the RARA rearrangement in the bone mar-
row was performed in five cases at the time of CNS relapse.
Three cases sustained a molecular remission (10, 12, 14).
Because an increasing number of reports have been pub-
lished on extramedullary localization in APL, at the time of
relapse, following the advent ATRA treatment, the question
arises as to whether treatment of APL with ATRA predisposes
patients to the development of extramedullary relapse. There
are two reports of CNS relapse after arsenic trioxide (AS2O3)
treatment (7, 9). Several biologic effects, modulated by ATRA,
have been suggested to play a role in extramedullary leukemic
infiltration, such as increased expression of certain adhesion
molecule (26, 27). It is possible that a similar differentiation
and regulation of adhesion molecules, as seen with ATRA
therapy, occurs with the use of AS2O3. The risk factors asso-
ciated with extramedullary relapse are high WBC count on
presentation and the ATRA syndrome (8, 13). A GIMEMA
study compared the relapse pattern in APL patients enrolled
into two consecutive large studies. Patients receiving ATRA,
in addition to chemotherapy, have no increased risk of devel-
oping extramedullary disease at the time of relapse as com-
pared with APL patients treated with chemotherapy alone.
However, higher prevalence of CNS involvement was detected
in patients receiving ATRA (28). In the literature review, only
three among 21 cases with CNS relapse received systemic
chemotherapy without ATRA.
Despite the impressive complete remission and survival
results of APL, the prognosis for relapsed APL is generally
poor. Treatment of CNS relapse consists of intrathecal chemo-
therapy, radiotherapy, systemic chemotherapy (with high-dose
cytarabine which passes through the blood brain barrier), and
agents for cytodifferentiation such as ATRA. Six cases with
CNS relapse were treated with combination therapy includ-
ing ATRA, and they achieved the complete remission as next
(5, 6, 12, 16, 17, 25). Four of the six cases who were treated
with ATRA for relapsed APL had received ATRA previously
(5, 6, 12, 25). The durations of their first complete remission
are 2, 6, 11 and 144 months. In our case, because he received
ATRA for maintenance therapy when the CNS relapse was
found, we treated him with intrathecal therapy and with high-
dose systemic chemotherapy. Recently, AS2O3 has represented
a useful salvage treatment for APL patients who relapsed after
or refractory to ATRA and chemotherapy (29). AS2O3 may
also be an option for patients with relapsed APL in the CNS.
In summary, we presented an APL case with meningeal re-
lapse. CNS involvement of APL is rare, but CNS is a possi-
ble site of relapse in a patient with complete remission after
treatment of APL. We think that it is necessary to do a com-
plete evaluation and diagnostic approach, including CSF stud-
ies, if CNS symptoms occur in patients with APL, even though
hematologic parameters sustain remission.
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